ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 83 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 2.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17 | +21.4% | 13,098 | -59.6% | 0.00% | +100.0% |
Q1 2023 | $14 | -99.9% | 32,386 | +118.6% | 0.00% | 0.0% |
Q3 2022 | $11,000 | -93.5% | 14,812 | -33.9% | 0.00% | -92.3% |
Q3 2019 | $170,000 | +40.5% | 22,425 | +0.2% | 0.01% | +85.7% |
Q1 2019 | $121,000 | +202.5% | 22,384 | +66.9% | 0.01% | +250.0% |
Q4 2018 | $40,000 | – | 13,414 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 507,191 | $5,107,000 | 0.50% |
Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |